Article
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
British journal of cancer - 10 Jul 2012
Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A
Abstract excerpt
BACKGROUND: KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although the mutational status of KRAS is reportedly highly concordant between primary and metastatic lesions, it is not yet clear whether genotoxic chemotherapies might induce additional mutations. METHODS: A total of 63 lesions (23 baseline primary, 18 metastatic and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.